Skip to content

A clinical trial to study the effects of an ointment made of Indian frankincense extract in patients with acute inflammatory conditions.

A Multicentric Randomized, Double Blind, Placebo Controlled Comparative Pilot Human Clinical Study to Assess the Efficacy and Tolerability of a Boswellia Serrata Extract Ointment in Patients with acute inflammatory conditions

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2017/03/008132
Enrollment
150
Registered
2017-03-17
Start date
Unknown
Completion date
Unknown
Last updated
2023-02-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Acute inflammatory conditions like sprain, strain, or contusion Health Condition 2: M708- Other soft tissue disorders related to use, overuse and pressure

Interventions

Intervention1: Boswellia serrata extract ointment: Topical application applied three times daily to cover the affected area Control Intervention1: Placebo Ointment: Topical application applied three t

Sponsors

Clinfound Clinical Research Services PvtLtd
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Male or female outpatients aged 18 to 65 years 2.Patients with acute inflammatory condition (within 72 hours of entry in the study) like sprain, strain, or contusion 3.Patients with a pain score > 5 on visual analog scale (VAS) 4.Patients ready to give written informed consent and willing to comply the study protocol

Exclusion criteria

Exclusion criteria: 1.Patients with an injury to the same body region within the prior 3 months or a lifetime history of 3 or more injuries to the injured body region 2.Use of NSAIDs (including acetaminophen) within 24 hours, opioids within 7 days, long acting NSAIDs like piroxicam or naproxem since the injury, any topical medication since injury or corticosteroid drugs by any route of administration within 60 days of entry in the study 3.Patients with an open lesion or serious injury, including a fracture, nerve injury, and a tear of ligament, muscle, or cartilage 4.Known hypersensitivity or intolerance or allergic type reactions to curcumin, boswellia or acetaminophen. 5.History of known alcohol, analgesic or narcotic abuse within 2 years. 6.Sensitive skin and loss of skin at the application site. 7.Pregnant or lactating females or absence of effective contraceptive methods for females of childbearing potential. 8.Presence of any severe medical or psychological condition or chronic condition/inflammation/infection that in the opinion of the investigator would compromise the patientâ??s safety or successful participation in the study. 9.Participation in any other clinical study within 30 days of screening.

Design outcomes

Primary

MeasureTime frame
Change in VAS score of painTimepoint: experienced during normal activity in the preceding 24 hours at end of study as compared to baseline

Secondary

MeasureTime frame
Pain relief scoreTimepoint: â??spontaneous pain reliefâ?? and â??pain relief during activity and movementâ?? at the end of study

Countries

India

Contacts

Public ContactDr Sreejith Sreekumar

Arjuna Natural Extracts Limited

drbinu@arjunanatural.com04842542480

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026